ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show - FiercePharma

1. ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show  FiercePharma
2. Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020  Business Wire
3. View Full Coverage on Google News

from Top stories - Google News https://ift.tt/2RLG05s
via gqrds